Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 save search
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
Published: 2022-03-21 (Crawled : 13:30) - biospace.com/
MDWD 2 d | $13.99 -0.14% -0.14% 110K
|
Health Technology
|
| O: 2.04%
H: 0.5%
C: -3.5%
phase 2 ces trial
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
Published: 2022-03-20 (Crawled : 12:20) - globenewswire.com
ATHA A | $3.715 -2.24% -2.29% 290K
|
Health Technology
| Email alert
Add to watchlist
alzheimer phase 2 trial disease alzheimer’s alzheimer's disease alzheimer's act-ad phase 2 fosgonimeton
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent, Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | $4.67 -5.08% -5.35% 2M
|
Health Technology
| Email alert
Add to watchlist
phase 2 one cancer mirvetuximab
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
Published: 2022-03-18 (Crawled : 12:30) - biospace.com/
RXRX P | $9.67 3.2% 3.1% 1.3M
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.95%
C: 3.61%
treatment phase 2 ces trial enroll rec-994
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Published: 2022-03-16 (Crawled : 00:00) - prnewswire.com
IONS S | $40.94 -0.63% -0.64% 590K
|
Health Technology
|
| O: -0.15%
H: 2.62%
C: 2.45%
phase 2 pos positive
Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial
Published: 2022-03-16 (Crawled : 13:00) - biospace.com/
ORMP | $2.06 0.0% 1.2M
|
Health Technology
|
| O: 2.48%
H: 4.79%
C: 4.29%
phase 2 trial enroll insulin nash
Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
OCUP | $3.53 0.86% 0.85% 69K
|
Health Technology
|
| O: 0.6%
H: 3.28%
C: 0.9%
apx3330 treatment phase 2 phase 2b trial 100 diabetic enroll diabetes
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
Published: 2022-03-16 (Crawled : 12:00) - biospace.com/
PTGX 4 | $14.33 -0.9% -0.91% 650K
|
Health Technology
|
| O: 2.01%
H: 1.1%
C: 0.57%
pn-235 phase 2 phase 2b trial therapeutics psoriasis one biotech iot milestone plague
U.K. Competition and Markets Authority to Refer Merger to a Phase 2 Review
Published: 2022-03-16 (Crawled : 08:00) - prnewswire.com
NLOK | $21.62 0.19%
|
Technology Services
|
| O: -3.39%
H: 0.69%
C: -10.24%
phase 2 merge
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic ShockOn track for top-line data in April 2022
Published: 2022-03-15 (Crawled : 20:00) - biospace.com/
WINT | $0.1694 2.11% 2.07% 880K
|
Health Technology
|
| O: 2.07%
H: 4.17%
C: -0.52%
phase 2 top-line data cardio star enroll topline
Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
REVB | $9.12 8.83% 8.11% 180K
|
|
| O: 9.8%
H: 63.39%
C: 11.61%
phase 2 phase 2b bioscience infection influenza enroll infections
MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
SNYNF | News | $98.55 0
|
Health Technology
|
| O: -3.03%
H: 3.21%
C: 3.21%
SNY | News | $46.02 -2.58% -2.65% 3.5M
|
Health Technology
|
| O: 3.07%
H: 0.0%
C: 0.0%
thio-101 phase 2 technology trial approval australia biotech iot
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
Published: 2022-03-15 (Crawled : 12:30) - globenewswire.com
ALEC M | $9.51 -0.52% -0.53% 630K
|
Health Technology
|
| O: 1.85%
H: 1.38%
C: -5.38%
al001 ema phase 2 trial
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
ARWR | $36.76 -0.68% -0.68% 610K
|
Health Technology
|
| O: 1.89%
H: 2.65%
C: 0.87%
treatment clearance phase 1 phase 2
Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Published: 2022-03-15 (Crawled : 12:00) - prnewswire.com
TRVI | $2.965 5.89% 5.56% 130K
|
Health Technology
|
| O: 2.27%
H: 14.07%
C: 8.15%
phase 2 trial therapeutics chronic cough enroll
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
AVXL | $11.27 -0.88% -0.89% 1.1M
|
Health Technology
|
| O: 0.4%
H: 6.32%
C: 5.24%
pdd-001 anavex phase 2 dementia anavex®2-73 parkinson conference presentation disease life science international tiona biomarkers
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
SAGE | $44.2 -0.88% -0.88% 400K
|
Health Technology
|
| O: 1.07%
H: 2.93%
C: 1.06%
sage-718 phase 2 air parkinson therapeutics presentation disease results
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
Published: 2022-03-15 (Crawled : 12:00) - globenewswire.com
PDSB | $8.59 -1.83% -1.86% 350K
|
Health Technology
|
| O: 0.2%
H: 7.86%
C: 7.27%
pds0101 phase 2 ces hpv trial cancer biotech iot tiona enroll
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
IDYA | $17.58 -0.17% -0.17% 390K
|
Health Technology
|
| O: -6.99%
H: 9.17%
C: -1.74%
ide397 idea phase 1 report bioscience phase 2 phase 3
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
Published: 2022-03-14 (Crawled : 22:00) - biospace.com/
ANAB | $25.82 -3.15% -3.25% 160K
|
Health Technology
|
| O: 0.31%
H: 2.23%
C: -0.97%
phase 2 trial acne report
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.